Celastrol (Cel) targets VDAC2 to induce mitochondria-dependent apoptosis and ROS-mediated ferroptosis in hepatocellular carcinoma (HCC), while its encapsulation in alkyl glucoside-modified liposomes (AGCL) enhances its anti-tumor efficacy and reduces side effects. This evidence concerns the gene VDAC2 and neoplasm.